Concepedia

Ke Zhang

KZ

Statistics

Publications

20

Citations

6.8K

H-Index

16

Active since

2012

Affiliations

Pfizer (United States)(Current)

Janssen (United States)

Peter MacCallum Cancer Centre

Royal Marsden Hospital

Ludwig-Maximilians-Universität München

Ke Zhang is an author at Pfizer (United States) specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2012–2025

20

Publications

20

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations

, , +17

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Jungsil Ro, Fabrice André et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

, , +10

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N., Neeraj Agarwal, Anders Bjartell et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

, , +17

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Kim N., Simon Chowdhury, Anders Bjartell et al. · Journal of Clinical Oncology · 2021 · 508 citations · Full text

, , +16

Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury et al. · European Urology · 2020 · 290 citations · Full text

, , +16

1–5 of 20